BACKGROUND: The clinical effectiveness of fecal microbiota transplant (FMT) for the treatment of recurrent Clostridium difficile infections (rCDI) has been demonstrated in randomized controlled trials. To assess the current status of FMT in Germany with respect to active centers, local standards, clinical effectiveness and safety, the MicroTrans Registry (NCT02681068) was established. METHODS: In a long-term retrospective multicenter observational study by the German Clinical Microbiome Study Group (GCMSG), primary and secondary cure on day 30 and 90, as well as occurrence of treatment-related adverse events were assessed. In addition to patient demographic data, we provide an overview of the FMT procedures and techniques used at different centers. RESULTS: Overall, 133 eligible patients from 33 centers were included, of which 64.7% were female (n = 86). The mean age was 75 years (interquartile range: 59.5-81.5). Administration via the duodenal route (n = 59; 44.4%) was the most frequently applied option, followed by colonic (n = 55; 41.1%), capsule (n = 13; 9.8%), and gastric administration (n = 4; 3.0%). Primary cure on day 30 and 90 was achieved in 84.2% (n = 101/120) and 78.3% (n = 72/92) of patients, respectively. Including re-treatment, secondary response was achieved in 87.5% (d 30; n = 105/120) and 85.9% (d 90; n = 79/92), respectively. Treatment- elated adverse events were documented in 16 patients (12.0%). CONCLUSION: FMT is a safe and effective treatment option for rCDI. However, FMT is currently available only in few centers in Germany, and treatment options vary from one center to another.
BACKGROUND: The clinical effectiveness of fecal microbiota transplant (FMT) for the treatment of recurrent Clostridium difficileinfections (rCDI) has been demonstrated in randomized controlled trials. To assess the current status of FMT in Germany with respect to active centers, local standards, clinical effectiveness and safety, the MicroTrans Registry (NCT02681068) was established. METHODS: In a long-term retrospective multicenter observational study by the German Clinical Microbiome Study Group (GCMSG), primary and secondary cure on day 30 and 90, as well as occurrence of treatment-related adverse events were assessed. In addition to patient demographic data, we provide an overview of the FMT procedures and techniques used at different centers. RESULTS: Overall, 133 eligible patients from 33 centers were included, of which 64.7% were female (n = 86). The mean age was 75 years (interquartile range: 59.5-81.5). Administration via the duodenal route (n = 59; 44.4%) was the most frequently applied option, followed by colonic (n = 55; 41.1%), capsule (n = 13; 9.8%), and gastric administration (n = 4; 3.0%). Primary cure on day 30 and 90 was achieved in 84.2% (n = 101/120) and 78.3% (n = 72/92) of patients, respectively. Including re-treatment, secondary response was achieved in 87.5% (d 30; n = 105/120) and 85.9% (d 90; n = 79/92), respectively. Treatment- elated adverse events were documented in 16 patients (12.0%). CONCLUSION: FMT is a safe and effective treatment option for rCDI. However, FMT is currently available only in few centers in Germany, and treatment options vary from one center to another.
Authors: G Cammarota; L Masucci; G Ianiro; S Bibbò; G Dinoi; G Costamagna; M Sanguinetti; A Gasbarrini Journal: Aliment Pharmacol Ther Date: 2015-03-01 Impact factor: 8.171
Authors: Manasi Agrawal; Olga C Aroniadis; Lawrence J Brandt; Colleen Kelly; Sarah Freeman; Christina Surawicz; Elizabeth Broussard; Neil Stollman; Andrea Giovanelli; Becky Smith; Eugene Yen; Apurva Trivedi; Levi Hubble; Dina Kao; Thomas Borody; Sarah Finlayson; Arnab Ray; Robert Smith Journal: J Clin Gastroenterol Date: 2016 May-Jun Impact factor: 3.062
Authors: Ilan Youngster; George H Russell; Christina Pindar; Tomer Ziv-Baran; Jenny Sauk; Elizabeth L Hohmann Journal: JAMA Date: 2014-11-05 Impact factor: 56.272
Authors: Els van Nood; Anne Vrieze; Max Nieuwdorp; Susana Fuentes; Erwin G Zoetendal; Willem M de Vos; Caroline E Visser; Ed J Kuijper; Joep F W M Bartelsman; Jan G P Tijssen; Peter Speelman; Marcel G W Dijkgraaf; Josbert J Keller Journal: N Engl J Med Date: 2013-01-16 Impact factor: 91.245
Authors: Alexander Kleger; Jacqueline Schnell; Andreas Essig; Martin Wagner; Martin Bommer; Thomas Seufferlein; Georg Härter Journal: Dtsch Arztebl Int Date: 2013-02-15 Impact factor: 5.594
Authors: Oliver A Cornely; Dilip Nathwani; Cristina Ivanescu; Olatunji Odufowora-Sita; Peny Retsa; Isaac A O Odeyemi Journal: J Antimicrob Chemother Date: 2014-07-28 Impact factor: 5.790
Authors: Rosemarie Peri; Rebeca Cruz Aguilar; Kester Tüffers; Andreas Erhardt; Alexander Link; Philipp Ehlermann; Wolfgang Angeli; Thorsten Frank; Martin Storr; Thomas Glück; Andreas Sturm; Ulrich Rosien; Frank Tacke; Oliver Bachmann; Philipp Solbach; Andreas Stallmach; Felix Goeser; Maria Jgt Vehreschild Journal: United European Gastroenterol J Date: 2019-03-21 Impact factor: 4.623
Authors: Andreas Stallmach; Arndt Steube; Philip Grunert; Michael Hartmann; Lena M Biehl; Maria J G T Vehreschild Journal: Dtsch Arztebl Int Date: 2020-01-17 Impact factor: 5.594
Authors: F Eun-Hyung Lee; John L Daiss; Natalie S Haddad; Sophia Nozick; Geena Kim; Shant Ohanian; Colleen S Kraft; Paulina A Rebolledo; Yun Wang; Hao Wu; Adam Bressler; Sang Nguyet Thi Le; Merin Kuruvilla; Martin C Runnstrom; Richard P Ramonell; L Edward Cannon Journal: J Clin Microbiol Date: 2022-03-16 Impact factor: 11.677
Authors: M Schmidt-Hieber; J Bierwirth; D Buchheidt; O A Cornely; M Hentrich; G Maschmeyer; E Schalk; J J Vehreschild; Maria J G T Vehreschild Journal: Ann Hematol Date: 2017-11-24 Impact factor: 3.673
Authors: Rodrigo Duarte-Chavez; Thomas R Wojda; Thomas B Zanders; Berhanu Geme; Gloria Fioravanti; Stanislaw P Stawicki Journal: J Glob Infect Dis Date: 2018 Apr-Jun
Authors: Gianluca Ianiro; Marcello Maida; Johan Burisch; Claudia Simonelli; Georgina Hold; Marco Ventimiglia; Antonio Gasbarrini; Giovanni Cammarota Journal: United European Gastroenterol J Date: 2018-06-03 Impact factor: 4.623